Clinical Investigation Center
The Shine On Project: hemangiosarcoma detection test
Enroll Now - Phase 3
Phase 3 is to determine if a test looking for specific cells in the blood can be used to detect hemangiosarcoma in its earliest stages, before a tumor has formed.
- Must be an AKC-registered or pedigreed Golden Retriever, Portuguese Water Dog, or Boxer.
- Dogs must be at least 6 years old and in good general health
- Owners must agree to submit blood samples for re-testing according to the study guidelines
- Dog/Owner must live in the contiguous 48 states
Dogs that have positive test results, and that do not have a detectable tumor, will have the option to receive the experimental drug, eBAT, to determine the drug's potential to prevent progression of disease.
Due to an overwhelming response and to the number of samples we can currently process in one week, responding to eligible participants will take longer than we anticipated.
Be assured that eligible participants' forms will be added to our list, and we will respond as quickly as time and space allow.
Treatment with eBAT will be done exclusively at the Veterinary Medical Center, University of Minnesota in St. Paul, MN.
NOTE: The Shine On study is not intended as a diagnostic for disease. It is an experiment to determine whether the blood test can be used as a tool for early detection of hemangiosarcoma. At this point, we do not know if a negative test result means the dog does not have, or will never get, hemangiosarcoma. We also do not know if a positive test result means that a dog will definitely get hemangiosarcoma. The study is designed to answer some of these questions.
See other tabs for more information on the phases of Shine On.
Phase 1 & 2
Current Status: Phase 1&2 Open and enrolling
Principal Investigator: Jaime Modiano, VMD, PhD
Contacts: Dr. Modiano: email@example.com
Amber Winter, Senior Research Study Technician, firstname.lastname@example.org, 612-624-1352
"Early Detection to Target Hemangiosarcoma Cells in Dogs (Shine On)" was conceived to reduce the mortality and the suffering caused by canine hemangiosarcoma. The goal of this project is to develop effective methods for early detection and for prevention of canine hemangiosarcoma. We will use a blood test to look for the cells responsible for establishing and maintaining the disease, and then use an experimental drug treatment that attacks those same cells in order to prevent development of the tumor.
Phase 1 is designed to refine the hemangiosarcoma diagnostic blood test. We are collecting blood samples from dogs in the four categories below, all from cases being seen at the Veterinary Medical Center only.
Category-1. Dogs with confirmed hemangiosarcoma. This group will include dogs that have a pathologically confirmed diagnosis of hemangiosarcoma from any anatomical site, at any stage of disease, of any pathological grade, and dogs can be of any breed, age and sex as long as samples are obtained prior to removal of gross tumor burden (primary or recurrent). Dogs in this group will be re-tested every 60 days in Phase 2. We expect to recruit 25 dogs into this group.
Category-2. Dogs with confirmed non-neoplastic (non-cancerous) splenic lesions. This group will include dogs that have a pathologically confirmed diagnosis of splenic nodular hyperplasia and/or splenic hematoma and/or splenic hemangioma. The disease can be at any stage and dogs can be of any breed, age and sex as long as samples are obtained prior to splenectomy. Dogs in this group will be re-tested at 6-month intervals in Phase 2. We expect to recruit 25 dogs into this group.
Category-3. Dogs with any confirmed cancer other than hemangiosarcoma. This group will include dogs that have a pathologically confirmed diagnosis of cancer other than hemangiosarcoma, specifically malignant lymphoma (any subtype), osteosarcoma, soft tissue sarcoma, or carcinoma. The cancer can be in any anatomical site, at any stage, have any pathological grade, and dogs can be of any breed, age and sex as long as samples are obtained prior to removal of gross tumor burden (primary or recurrent). Dogs in this group will be re-tested at 6-month intervals in Phase 2. We expect to recruit at least 25 dogs, and potentially up to 75 dogs into this group.
Category-4. Healthy young dogs. This group will include young dogs (under four years of age) with no evidence of any disease recruited from our general practice well-health program and from the hospital staff pet population. We expect to recruit at least 25 dogs into this group.
Phase 2 is designed to determine the ability of the diagnostic blood test to predict relapse in dogs with hemangiosarcoma that are undergoing treatment. This phase is limited to dogs recruited as part of Phase 1, and will be completed at the end of year 3 by retesting dogs in the groups as described above.
Phase 3 is studying the hemangiosarcoma detection test in early detection and prevention of hemangiosarcoma in purebred Golden Retrievers, Portuguese Water Dogs and Boxers. See 'Enroll Now' tab for to check eligibility and to enroll.
Support the project
Allow your dog to participate, if eligible
Tell your friends and family about the study and encouraging them to allow their dogs to participate, if eligible
Provide financial support that will help us expand and accelerate recruitment and progress by contacting Andrea Fahrenkrug at email@example.com or by following this link to the Dr. Modiano Oncology Research Fund